THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Profit vs. patience

Pressure from Carl Icahn clouds the future of the state’s two largest biotechs

Genzyme chief executive Henri Termeer said Carl Ichan notified him of his interest in securing four seats on the company’s board on Feb. 19. Genzyme chief executive Henri Termeer said Carl Ichan notified him of his interest in securing four seats on the company’s board on Feb. 19. (Michele Mcdonald for The Boston Globe)
By Robert Weisman
Globe Staff / February 28, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Veronica Eulacio, a 21-year-old college student born in Venezuela, suffers from Gaucher disease, a rare enzyme deficiency that causes enlargement of her liver and spleen. Thanks to Cerezyme, a drug made by Genzyme Corp. that she’s injected since she was a child, Eulacio is living a normal life, studying architecture at Ball State University in Indiana. (Full article: 1168 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass